Incidence of platinum‐induced ototoxicity in pediatric patients in Quebec

Peleva, Emilia; Emami, Nader; Alzahrani, Mohammad Ghormallah; Bezdjian, Aren; Gurberg, Joshua; Carret, Anne Sophie; Daniel, Sam J.

doi:10.1002/pbc.25123

Cited by 40 publications

(44 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of hearing loss is hard to compare in different study populations because of differences in diagnostic groups, cancer treatment, and type of auditory grading. In previous studies the prevalence of questionnaire-reported hearing loss in groups at risk of ototoxicity ranged from 16 to 31% [2,4,21], and was even higher when prevalence was assessed by retrospective data collection in medical records (12–90%) [3,22–24]. However, previous studies that are similar to ours may have underestimated the prevalence of hearing loss just as our study did for mild and unilateral hearing loss.…”

Section: Discussionsupporting

confidence: 45%

Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study

et al. 2017

View full text Add to dashboard Cite

BackgroundHearing loss is a potential late effect after childhood cancer. Questionnaires are often used to assess hearing in large cohorts of childhood cancer survivors and it is important to know if they can provide valid measures of hearing loss. We therefore assessed agreement and validity of questionnaire-reported hearing in childhood cancer survivors using medical records as reference.ProcedureIn this validation study, we studied 361 survivors of childhood cancer from the Swiss Childhood Cancer Survivor Study (SCCSS) who had been diagnosed after 1989 and had been exposed to ototoxic cancer treatment. Questionnaire-reported hearing was compared to the information in medical records. Hearing loss was defined as ≥ grade 1 according to the SIOP Boston Ototoxicity Scale. We assessed agreement and validity of questionnaire-reported hearing overall and stratified by questionnaire respondents (survivor or parent), sociodemographic characteristics, time between follow-up and questionnaire and severity of hearing loss.ResultsQuestionnaire reports agreed with medical records in 85% of respondents (kappa 0.62), normal hearing was correctly assessed in 92% of those with normal hearing (n = 249), and hearing loss was correctly assessed in 69% of those with hearing loss (n = 112). Sensitivity of the questionnaires was 92%, 74%, and 39% for assessment of severe, moderate and mild bilateral hearing loss; and 50%, 33% and 10% for severe, moderate and mild unilateral hearing loss, respectively. Results did not differ by sociodemographic characteristics of the respondents, and survivor- and parent-reports were equally valid.ConclusionsQuestionnaires are a useful tool to assess hearing in large cohorts of childhood cancer survivors, but underestimate mild and unilateral hearing loss. Further research should investigate whether the addition of questions with higher sensitivity for mild degrees of hearing loss could improve the results.

show abstract

Section: Discussionsupporting

confidence: 45%

Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there has been no reported incidence of cisplatin based hearing loss in the head and neck cancer population. Within the pediatric population, there has been report of as much as 30% clinically significant 2 Advances in Otolaryngology hearing loss [10]. In head and neck cancer, chemotherapy is also combined with radiation for advanced tumors which may work synergistically with cisplatin to increase the risk of hearing loss.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Cisplatin Induced Ototoxicity in Adults with Head and Neck Cancer

Greene

Standring

Siddiqui

et al. 2015

Advances in Otolaryngology

View full text Add to dashboard Cite

Objective. To elucidate the incidence of cisplatin induced ototoxicity in adult patients, with a focus on an adult population. Study Design. IRB approved retrospective study. Methods. The charts of patients who underwent cisplatin therapy from 1995 to present were reviewed. Inclusion criteria were (1) cisplatin as the primary chemotherapeutic agent and (2) hearing evaluation performed prior to and after treatment. Audiometric thresholds were measured by presenting pure-tone stimuli at 0.25 to 10.0 kHz. Criteria for hearing loss were based on the Chang criteria. Cochlear radiation doses were also calculated in patients with primary tumors in their head and neck or brain. Results. There were 1565 patients that had undergone therapy with cisplatin from 1995 to 2014, which 30 met inclusion criteria. Eight were patients treated for head and neck or brain cancer. Evaluation with ANOVA testing identified statistically significant decline in audiometric scores for WRS and pure tone frequencies 500, 2000, 4000, 6000, and 8000 Hz in the right ear. Overall, hearing loss was noted with 63% incidence and in patients who received radiation to their cochlea and cisplatin. Conclusion. The incidence of cisplatin induced ototoxicity was significant and even more prevalent in those patients receiving both cisplatin and radiation to their cochlea.

show abstract

“…In patients receiving carboplatin, the incidence of ototoxicity is approximately 7% (Dean et al, 2008; Jehanne et al, 2009). In patients receiving cumulative cisplatin doses of ≤200 mg/m 2 , 200–400 mg/m 2 , and ≥400 mg/m 2 , the incidence increases to 59, 68, and 65%, respectively (Peleva et al, 2014). Moreover, severe nephrotoxicity has not been reported during carboplatin-therapy and reduction of glomerular filtration rate to less than 50% is less frequent than with cisplatin.…”

Section: Managementmentioning

confidence: 99%

Hypersensitivity to Carboplatin in Children with Malignancy

et al. 2017

View full text Add to dashboard Cite

Purpose: Carboplatin-based regimens have proven efficacy in children with cancer. However, the development of hypersensitivity reactions (HSRs) may have a negative impact on treatment intensity and patients’ outcome. The aim of this review is to summarize the incidence and the clinical features of HSRs occurring in children with cancer treated with carboplatin and their impact on treatment efficacy.Methods: Data were collected by searching for relevant studies on the incidence, clinical features and management of possible side effects about the use of carboplatin in children, published from March 1987 to October 2016 in the PubMed database.Results: Carboplatin HSRs present with mild/moderate to severe clinical patterns. The risk of HSR is related to the cumulative number of infusions. Moreover, a greater risk of developing an HSR has been observed in younger patients than in older age groups of children; risk is also greater in girls and in patients with a prior history of allergy to other drugs. Management options include cessation of carboplatin and switching to another agent, premedication with antihistamines and/or corticosteroids, and carboplatin desensitization. For sensitized patients who have obtained benefits from carboplatin, the continuation of the treatment is desirable and desensitization protocols have showed promising results.Conclusion: Clinicians must not underestimate the potential risk and occurrence of carboplatin HSRs in the pediatric population in order to outline adequate management strategies. Desensitization protocols should be considered for patients sensitive to carboplatin in order to avoid having to discontinue an effective chemotherapy.

show abstract

Incidence of platinum‐induced ototoxicity in pediatric patients in Quebec

Abstract: Ototoxicity following chemotherapy with cisplatin or carboplatin is common and can frequently progress after the completion of treatment. Long-term follow-up is strongly recommended.

Cited by 40 publications

References 33 publications

Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study

Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study

Incidence of Cisplatin Induced Ototoxicity in Adults with Head and Neck Cancer

Hypersensitivity to Carboplatin in Children with Malignancy

Contact Info

Product

Resources

About